Glastad Invest
Glastad Invest AS is a venture capital and private equity firm based in Farsund, Norway, with additional offices in London and Oslo. The firm specializes in direct investments across a diverse range of companies, from early seed stages to those that are post-IPO, including late-stage ventures and turnarounds. Glastad Invest focuses on middle market, growth capital, and mature companies, primarily in emerging technologies such as information technology, telecommunications, medical devices, media, energy, environmental, and marine technology, as well as biomarine and financial services. The firm invests in companies located in Scandinavia, the United Kingdom, and the United States, and seeks to secure board representation through direct investments or co-investors. Glastad Invest typically aims for an exit between two and seven years, without restricting the size of its potential investments. It operates as a subsidiary of Glastad Holding, a family-owned company with historical ties to the shipping industry.
SantoSolve AS is a biotechnology company based in Oslo, Norway, focused on developing topical analgesic products for pain management. Founded in 1994, the company has created 2PX, a pharmaceutical formulation designed for topical administration, which has demonstrated effectiveness in treating both nociceptive and neuropathic pain. The development of 2PX is grounded in the use of non-radioactive strontium as the active ingredient, which has shown strong local analgesic effects in various pain conditions and has not been associated with significant adverse effects. Phase I safety and pharmacology studies indicated low systemic bioavailability and only minor side effects at the application site. The product has successfully completed open label Phase II clinical trials, proving its strong analgesic effect, particularly in patients with osteoarthritis. These results have been further corroborated by placebo-controlled trials, which confirmed that 2PX provides a statistically superior analgesic effect compared to placebo treatments.